Alnylam Pharmaceuticals (ALNY) Announces Orphan Drug Status for ALN-TTR02
Tweet Send to a FriendGet Alerts ALNY Hot Sheet
Up)
Trade ALNY Now!
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) said the FDA has provided Orphan Drug Designation to ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic polyneuropathy (FAP), one of the predominant clinical manifestations of transthyretin (TTR)-mediated amyloidosis (ATTR).
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Alnylam (ALNY) Updates on Preclinical Data for RNAi Program Targeting ALAS-1
- Palatin Technologies, Inc. (PTN) Reports Q1 Loss of $0.04; Updates Bremelanotide Development
- Mylan (MYL) Launches Generic Tricor Tabs (ABBV)
Create E-mail Alert Related Categories
FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
